Associated tags: Adverum Biotechnologies, Neovascularization, Biotechnology, Standard of care, Patient, Paratriathlon, Research, IVT, Pharmaceutical industry, AMD, OPTIC, Safety, Severe cognitive impairment, Annual general meeting
Locations: REDWOOD CITY, CA, US, TD
Retrieved on:
понедельник, марта 18, 2024
Research,
Adverum Biotechnologies,
Vasculitis,
Three Months,
Macula,
Chorioretinitis,
Inflammation,
Patient,
Episcleritis,
American Academy,
Anti-VEGF,
LUNA,
Intraocular pressure,
Investment,
Clinical trial,
Injection,
Safety,
Drug development,
Paratriathlon,
AMD,
AAO,
OPTIC,
Retinitis,
CST,
Vascular occlusion,
Annual general meeting,
VEGF,
Pharmaceutical industry REDWOOD CITY, Calif., March 18, 2024 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company pioneering the use of gene therapy as a new standard of care for highly prevalent ocular diseases, today reported financial results for the fourth quarter and full year 2023. The company also provided recent pipeline highlights and corporate updates.
Key Points:
- The company also provided recent pipeline highlights and corporate updates.
- 85% and 68% of patients at the 2E11 and 6E10 doses, respectively, received no supplemental injections through 26 weeks.
- Stock-based compensation expense included in research and development expenses was $1.0 million for the fourth quarter of 2023.
- Stock-based compensation expense included in general and administrative expenses was $3.1 million for the fourth quarter of 2023.
REDWOOD CITY, Calif., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company pioneering the use of gene therapy as a new standard of care for highly prevalent ocular diseases, today announced that Laurent Fischer, M.D., president and chief executive officer of Adverum Biotechnologies, will participate in the Ophthalmology Corporate Panel Discussion at the TD Cowen 44th Annual Health Care Conference on Tuesday, March 5th, 2024 at 9:10 a.m.
Key Points:
- REDWOOD CITY, Calif., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company pioneering the use of gene therapy as a new standard of care for highly prevalent ocular diseases, today announced that Laurent Fischer, M.D., president and chief executive officer of Adverum Biotechnologies, will participate in the Ophthalmology Corporate Panel Discussion at the TD Cowen 44th Annual Health Care Conference on Tuesday, March 5th, 2024 at 9:10 a.m.
- ET.
- The on-demand webcast of the panel discussion may be accessed under Events and Presentations in the Investors section of Adverum’s website.
- A replay of the webcast will be available on the website for at least 30 days following the presentation.
Retrieved on:
понедельник, февраля 12, 2024
REDWOOD CITY, Calif., Feb. 12, 2024 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases, today announced that Laurent Fischer, M.D., president and chief executive officer of Adverum Biotechnologies, will present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference on Tuesday, February 13th, 2024 at 12:00 p.m.
Key Points:
- REDWOOD CITY, Calif., Feb. 12, 2024 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases, today announced that Laurent Fischer, M.D., president and chief executive officer of Adverum Biotechnologies, will present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference on Tuesday, February 13th, 2024 at 12:00 p.m.
- ET.
- The on-demand webcast corporate presentation may be accessed under Events and Presentations in the Investors section of Adverum’s website.
- A replay of the webcast will be available on the website for at least 30 days following the presentation.
Chorioretinitis,
Injection,
Principal,
Inflammation,
Life,
Adverum Biotechnologies,
VEGF,
AMD,
Partner (business rank),
Vasculitis,
Patient,
Safety,
Paratriathlon,
Prednisone,
University of Nevada, Reno,
Intraocular pressure,
Data,
Webcast,
University,
Retinitis,
M.A,
Clinical research,
CST,
Vascular occlusion,
Pharmaceutical industry These data are being presented by Dr. Arshad Khanani today at the 47th Annual Meeting of the Macula Society.
Key Points:
- These data are being presented by Dr. Arshad Khanani today at the 47th Annual Meeting of the Macula Society.
- “Wet AMD is a leading cause of blindness in people over the age of 65, requiring life-long anti-VEGF injections.
- Our goal with Ixo-vec is to provide patients virtually injection-free management of their wet AMD lasting years and potentially for life,” stated Laurent Fischer, M.D., president and chief executive officer of Adverum Biotechnologies.
- The LUNA trial builds on our experience with the OPTIC study, where landmark 2-year data was recently published in The Lancet’s eclinicalmedicine.
Retrieved on:
понедельник, февраля 5, 2024
REDWOOD CITY, Calif., Feb. 05, 2024 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases, today announced that it has agreed to sell approximately 106.25 million shares of its common stock (or pre-funded warrants in lieu thereof) to a select group of institutional and accredited healthcare specialist investors in a private placement, at a price per share of $1.20, representing a premium of approximately 20% to Adverum’s 30-day volume-weighted average price. The financing is expected to close on February 8, 2024, subject to customary closing conditions. Adverum anticipates the gross proceeds from the private placement to be approximately $127.5 million, before deducting any offering related expenses.
Key Points:
- The financing is expected to close on February 8, 2024, subject to customary closing conditions.
- Adverum anticipates the gross proceeds from the private placement to be approximately $127.5 million, before deducting any offering related expenses.
- The proceeds from this financing, combined with current cash, cash equivalents and marketable securities, are expected to be sufficient to fund the current operating plan into late 2025.
- Adverum has agreed to file a registration statement with the U.S. Securities and Exchange Commission (the “SEC”) registering the resale of the shares of common stock issued in this private placement.
AMD,
Safety,
Medicine,
University of Nevada, Reno,
Weill Cornell Medicine,
News,
LUNA,
Adverum Biotechnologies,
University,
M.A,
Webcast,
Clinical research,
Pharmaceutical industry REDWOOD CITY, Calif., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases, today announced that the company will host a webcast to review preliminary efficacy and safety data from its ongoing LUNA Phase 2 study of ixoberogene soroparvovec (Ixo-vec) for the treatment of wet age-related macular degeneration (wet AMD) on Thursday, February 8th, 2024 at 8:00am ET. The webcast will include Szilard Kiss, M.D., Professor of Ophthalmology at Weill Cornell Medical College and an investigator in Adverum’s LUNA Phase 2 study. Adverum will further detail these preliminary results at the 47th Annual Meeting of the Macula Society. The preliminary LUNA results will include safety and efficacy data at both the 2E11 and 6E10 dose levels. LUNA was fully enrolled in August 2023.
Key Points:
- The webcast will include Szilard Kiss, M.D., Professor of Ophthalmology at Weill Cornell Medical College and an investigator in Adverum’s LUNA Phase 2 study.
- Adverum will further detail these preliminary results at the 47th Annual Meeting of the Macula Society.
- The preliminary LUNA results will include safety and efficacy data at both the 2E11 and 6E10 dose levels.
- Adverum will host a conference call and webcast on Thursday, February 8th, 2024 at 8:00 am ET to discuss the preliminary safety and efficacy data from the LUNA Phase 2 study of Ixo-vec.
Retrieved on:
понедельник, января 29, 2024
Drug,
Conditional sentence,
Spark Therapeutics,
Translation,
Patient,
Therapy,
Employment,
Paratriathlon,
AAV,
Universities of Lille,
Innovation,
Pfizer,
LUNA,
AMD,
Adverum Biotechnologies,
Drug discovery,
CNS,
Pharmaceutical industry REDWOOD CITY, Calif., Jan. 29, 2024 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases, today announced that Romuald “Romu” Corbau, Ph.D., has joined Adverum as the company’s chief scientific officer.
Key Points:
- REDWOOD CITY, Calif., Jan. 29, 2024 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases, today announced that Romuald “Romu” Corbau, Ph.D., has joined Adverum as the company’s chief scientific officer.
- “On behalf of the entire team at Adverum, I am delighted to welcome Dr. Corbau as the newest member of our executive leadership team.
- Dr. Corbau joins Adverum from GenEdit, where he served as Chief Scientific Officer.
- Prior to joining GenEdit, Dr. Corbau progressed from Vice President of Research to Chief Scientific Officer at Freeline, a clinical stage company developing AAV-vector mediated systemic gene therapies for chronic diseases.
Adverum Biotechnologies,
Medicine,
University,
M.A,
University of Nevada, Reno,
Safety,
LUNA,
Clinical research,
News,
Pharmaceutical industry “We are very pleased to have the opportunity to present our initial Phase 2 efficacy and safety data from the LUNA study at the Macula Society meeting” stated Laurent Fischer, M.D., president and chief executive officer of Adverum Biotechnologies.
Key Points:
- “We are very pleased to have the opportunity to present our initial Phase 2 efficacy and safety data from the LUNA study at the Macula Society meeting” stated Laurent Fischer, M.D., president and chief executive officer of Adverum Biotechnologies.
- “We recently received confirmation that our abstract was accepted and we are delighted to present at a medical conference focused on groundbreaking advances in retinal and macular diseases.
- The presentation from the 47th Annual Macula Society Meeting will also be made available on Adverum’s website under News & Publications and through the following link: https://adverum.com/news-publications .
- *Preliminary schedule with the exact date and time of presentation subject to change.
REDWOOD CITY, Calif., Nov. 28, 2023 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases, today announced that Linda Rubinstein, chief financial officer, and Star Seyedkazemi, chief development officer of Adverum Biotechnologies, will participate in a fireside chat at the Evercore ISI 6th Annual HealthCONx Conference on Wednesday, November 29, 2023 at 3:50 p.m.
Key Points:
- REDWOOD CITY, Calif., Nov. 28, 2023 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases, today announced that Linda Rubinstein, chief financial officer, and Star Seyedkazemi, chief development officer of Adverum Biotechnologies, will participate in a fireside chat at the Evercore ISI 6th Annual HealthCONx Conference on Wednesday, November 29, 2023 at 3:50 p.m.
- ET in Miami, Florida.
- The on-demand webcast corporate presentation may be accessed under Events and Presentations in the Investors section of Adverum’s website.
- A replay of the webcast will be available on the website for 90 days following the presentation.
Drug development,
Three Months,
Ophthalmology,
Safety,
Annual general meeting,
Research,
American Academy of Ophthalmology,
Gene,
Allergan,
Investment,
Anti-VEGF,
American Academy,
Data,
Patient,
Cell,
LUNA,
OPTIC,
AAO,
AMD,
NHP,
CMC,
Injection,
CST,
Inflammation,
Pharmaceutical industry,
Dietary supplement,
Medical imaging,
Medical device,
Cryptocurrency,
Adverum Biotechnologies REDWOOD CITY, Calif., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases, today reported financial results for the third quarter ended September 30, 2023.
Key Points:
- “In our OPTIC presentation at AAO, we’ve built upon our industry leading dataset in wet AMD gene therapy,” stated Laurent Fischer, M.D., president and chief executive officer of Adverum Biotechnologies.
- Scientific Meeting Presentations: In October 2023, Adverum showcased non-clinical data in two presentations at the European Society of Cell and Gene Therapy 2023 Annual Meeting.
- Stock-based compensation expense included in research and development expenses was $1.2 million for the third quarter of 2023.
- Stock-based compensation expense included in general and administrative expenses was $3.2 million for the third quarter of 2023.
